An AIDS activist group has filed a lawsuit against the Trump administration, alleging it failed to disclose a critical research and development agreement tied to a $1.3 billion settlement with Gilead Sciences over patents for HIV prevention drugs.
The settlement resolved a six-year legal dispute initiated by the previous Trump administration after the Centers for Disease Control and Prevention (CDC) accused Gilead of infringing its patent rights. The CDC had contributed to academic research that later underpinned the development of two widely used HIV medications: Truvada and Descovy.
The administration had alleged that Gilead:
- Ignored contributions from CDC scientists,
- Overstated its role in developing HIV prevention drugs, and
- Refused to sign a licensing agreement despite multiple attempts,
while profiting hundreds of millions of dollars from taxpayer-funded research.
Related articles
Do 'Blue Zones' Really Prove Longevity? Experts Weigh the Science
Below is a lightly edited, AI-generated transcript of the “First Opinion Podcast” interview with Shelley Wood and Eric Topol. Be sure to sign up for t...
Health Policy Experts Analyze Vaccines, Vaping, Drug Costs, and TrumpRx on Major Networks
KFF Health News chief Washington correspondent Julie Rovner discussed federal policy on vaccine research, vaping, and drug access on Science Friday on...
FDA Drug Center Acting Director Tracy Beth Høeg Departs Amid Leadership Changes
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, is leaving the agency, according to three sources...
Robert F. Kennedy Jr. Balances Vaccine Skepticism with Ohio Outreach Tour
Here in Washington, we’ve been hearing about tensions between the White House and one of its most controversial — but, at least in some circles, most...
STAT+ Roundup: New Hires and Promotions in Biotech and Pharma
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others....
UK Political Shake-Up Could Reshape Global Drug Pricing Policies
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congrats on...
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
Minnesota Lawmaker Proposes Redirecting Healthcare Tax to Boost Hospital Charity Care
Minnesota lawmakers are wrestling with how to sustain the state’s financially distressed hospitals while patients confront growing medical debt. One M...